1-20 of 22
A. John Iafrate
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Cell-Free HPV DNA Provides an Accurate and Rapid Diagnosis of HPV-Associated Head and Neck Cancer

Giulia Siravegna, Connor J. O'Boyle, Shohreh Varmeh, Natalia Queenan, Alexa Michel, Jarrod Stein, Julia Thierauf, Peter M. Sadow, William C. Faquin, Simon K. Perry, Adam Z. Bard, Wei Wang, Daniel G. Deschler, Kevin S. Emerick, Mark A. Varvares, Jong C. Park, John R. Clark, Annie W. Chan, Vanessa Carlota Andreu Arasa, Osamu Sakai, Jochen Lennerz, Ryan B. Corcoran, Lori J. Wirth, Derrick T. Lin, A. John Iafrate, Jeremy D. Richmon, Daniel L. Faden
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (4): 719–727.
https://doi.org/10.1158/1078-0432.CCR-21-3151
Published: 15 February 2022
View article titled, Cell-Free HPV DNA Provides an Accurate and Rapid Diagnosis of HPV-Associated Head and Neck Cancer
Open the PDF for Cell-Free HPV DNA Provides an Accurate and Rapid Diagnosis of HPV-Associated Head and Neck Cancer in another window
Includes: Supplementary data
Journal Articles

Pathology: Hub and Integrator of Modern, Multidisciplinary [Precision] Oncology

The AACR Pathology Task Force, Carolyn C. Compton, Angelo M. De Marzo, Jayanta Debnath, Keith D. Eaton, Kojo Elenitoba-Johnson, Michelangelo Fiorentino, Christopher A. French, Thomas J. Fuchs, Felice Giangaspero, Jiaoti Huang, A. John Iafrate, Michael M. Ittmann, Roy A. Jensen, Annette S. Kim, Massimo Loda, Robin G. Lorenz, Tamara L. Lotan, Anirban Maitra, Gerrit A. Meijer, Richard N. Mitchell, Anil V. Parwani, Francesco Pezzella, Eli Pikarsky, Jorge S. Reis-Filho, Andrea L. Richardson, Mark A. Rubin, Lawrence D. True
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (2): 265–270.
https://doi.org/10.1158/1078-0432.CCR-21-1206
Published: 19 January 2022
View article titled, Pathology: Hub and Integrator of Modern, Multidisciplinary [Precision] Oncology
Open the PDF for Pathology: Hub and Integrator of Modern, Multidisciplinary [Precision] Oncology in another window
Journal Articles

Tumor Tissue- versus Plasma-based Genotyping for Selection of Matched Therapy and Impact on Clinical Outcomes in Patients with Metastatic Breast Cancer

Neelima Vidula, Andrzej Niemierko, Giuliana Malvarosa, Megan Yuen, Jochen Lennerz, A. John Iafrate, Seth A. Wander, Laura Spring, Dejan Juric, Steven Isakoff, Jerry Younger, Beverly Moy, Leif W. Ellisen, Aditya Bardia
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (12): 3404–3413.
https://doi.org/10.1158/1078-0432.CCR-20-3444
Published: 15 June 2021
View article titled, Tumor Tissue- versus Plasma-based Genotyping for Selection of Matched Therapy and Impact on Clinical Outcomes in Patients with Metastatic Breast Cancer
Open the PDF for Tumor Tissue- versus Plasma-based Genotyping for Selection of Matched Therapy and Impact on Clinical Outcomes in Patients with Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Identification of Somatically Acquired BRCA1/2 Mutations by cfDNA Analysis in Patients with Metastatic Breast Cancer

Neelima Vidula, Taronish Dubash, Michael S. Lawrence, Antoine Simoneau, Andrzej Niemierko, Erica Blouch, Becky Nagy, Whijae Roh, Brian Chirn, Brittany A. Reeves, Giuliana Malvarosa, Jochen Lennerz, Steven J. Isakoff, Dejan Juric, Douglas Micalizzi, Seth Wander, Laura Spring, Beverly Moy, Kristen Shannon, Jerry Younger, Richard Lanman, Mehmet Toner, A. John Iafrate, Gad Getz, Lee Zou, Leif W. Ellisen, Shyamala Maheswaran, Daniel A. Haber, Aditya Bardia
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (18): 4852–4862.
https://doi.org/10.1158/1078-0432.CCR-20-0638
Published: 15 September 2020
View article titled, Identification of Somatically Acquired <em>BRCA1/2</em> Mutations by cfDNA Analysis in Patients with Metastatic Breast Cancer
Open the PDF for Identification of Somatically Acquired <em>BRCA1/2</em> Mutations by cfDNA Analysis in Patients with Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal Cancers

Aparna R. Parikh, Amikasra Mojtahed, Jaime L. Schneider, Katie Kanter, Emily E. Van Seventer, Isobel J. Fetter, Ashraf Thabet, Madeleine G. Fish, Bezaye Teshome, Kathryn Fosbenner, Brandon Nadres, Heather A. Shahzade, Jill N. Allen, Lawrence S. Blaszkowsky, David P. Ryan, Bruce Giantonio, Lipika Goyal, Ryan D. Nipp, Eric Roeland, Colin D. Weekes, Jennifer Y. Wo, Andrew X. Zhu, Dora Dias-Santagata, A. John Iafrate, Jochen K. Lennerz, Theodore S. Hong, Giulia Siravegna, Nora Horick, Jeffrey W. Clark, Ryan B. Corcoran
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (8): 1877–1885.
https://doi.org/10.1158/1078-0432.CCR-19-3467
Published: 15 April 2020
View article titled, Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal Cancers
Open the PDF for Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal Cancers in another window
Includes: Supplementary data
Journal Articles

FGFR1 Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor–Positive (HR+) Breast Cancer

Joshua Z. Drago, Luigi Formisano, Dejan Juric, Andrzej Niemierko, Alberto Servetto, Seth A. Wander, Laura M. Spring, Neelima Vidula, Jerry Younger, Jeffrey Peppercorn, Megan Yuen, Giuliana Malvarosa, Dennis Sgroi, Steven J. Isakoff, Beverly Moy, Leif W. Ellisen, A. John Iafrate, Carlos L. Arteaga, Aditya Bardia
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (21): 6443–6451.
https://doi.org/10.1158/1078-0432.CCR-19-0138
Published: 01 November 2019
View article titled, <em>FGFR1</em> Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor–Positive (HR<sup>+</sup>) Breast Cancer
Open the PDF for <em>FGFR1</em> Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor–Positive (HR<sup>+</sup>) Breast Cancer in another window
Includes: Supplementary data
Journal Articles

PI3K/AKT/mTOR Pathway Alterations Promote Malignant Progression and Xenograft Formation in Oligodendroglial Tumors

Kensuke Tateishi, Taishi Nakamura, Tareq A. Juratli, Erik A. Williams, Yuko Matsushita, Shigeta Miyake, Mayuko Nishi, Julie J. Miller, Shilpa S. Tummala, Alexandria L. Fink, Nina Lelic, Mara V.A. Koerner, Yohei Miyake, Jo Sasame, Kenji Fujimoto, Takahiro Tanaka, Ryogo Minamimoto, Shigeo Matsunaga, Shigeo Mukaihara, Takashi Shuto, Hiroki Taguchi, Naoko Udaka, Hidetoshi Murata, Akihide Ryo, Shoji Yamanaka, William T. Curry, Dora Dias-Santagata, Tetsuya Yamamoto, Koichi Ichimura, Tracy T. Batchelor, Andrew S. Chi, A. John Iafrate, Hiroaki Wakimoto, Daniel P. Cahill
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (14): 4375–4387.
https://doi.org/10.1158/1078-0432.CCR-18-4144
Published: 15 July 2019
View article titled, PI3K/AKT/mTOR Pathway Alterations Promote Malignant Progression and Xenograft Formation in Oligodendroglial Tumors
Open the PDF for PI3K/AKT/mTOR Pathway Alterations Promote Malignant Progression and Xenograft Formation in Oligodendroglial Tumors in another window
Includes: Supplementary data
Journal Articles

A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations

Martin H. Voss, Cinta Hierro, Rebecca S. Heist, James M. Cleary, Funda Meric-Bernstam, Josep Tabernero, Filip Janku, Leena Gandhi, A. John Iafrate, Darrell R. Borger, Nobuya Ishii, Youyou Hu, Yulia Kirpicheva, Valerie Nicolas-Metral, Anna Pokorska-Bocci, Anne Vaslin Chessex, Claudio Zanna, Keith T. Flaherty, Jose Baselga
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (9): 2699–2707.
https://doi.org/10.1158/1078-0432.CCR-18-1959
Published: 01 May 2019
View article titled, A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring <em>FGFR</em> Gene Alterations
Open the PDF for A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring <em>FGFR</em> Gene Alterations in another window
Includes: Supplementary data
Journal Articles

Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-mutant Lung Cancer

Ibiayi Dagogo-Jack, Pablo Martinez, Beow Y. Yeap, Chiara Ambrogio, Lorin A. Ferris, Christine Lydon, Tom Nguyen, Nicholas A. Jessop, A. John Iafrate, Bruce E. Johnson, Jochen K. Lennerz, Alice T. Shaw, Mark M. Awad
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (1): 158–165.
https://doi.org/10.1158/1078-0432.CCR-18-2062
Published: 03 January 2019
View article titled, Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-mutant Lung Cancer
Open the PDF for Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-mutant Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma

Kensuke Tateishi, A. John Iafrate, Quan Ho, William T. Curry, Tracy T. Batchelor, Keith T. Flaherty, Maristela L. Onozato, Nina Lelic, Sudhandra Sundaram, Daniel P. Cahill, Andrew S. Chi, Hiroaki Wakimoto
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (17): 4452–4465.
https://doi.org/10.1158/1078-0432.CCR-15-2274
Published: 31 August 2016
View article titled, Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma
Open the PDF for Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma in another window
Includes: Supplementary data
Journal Articles

Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate

Ovidiu C. Andronesi, Franziska Loebel, Wolfgang Bogner, Małgorzata Marjańska, Matthew G. Vander Heiden, A. John Iafrate, Jorg Dietrich, Tracy T. Batchelor, Elizabeth R. Gerstner, William G. Kaelin, Andrew S. Chi, Bruce R. Rosen, Daniel P. Cahill
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (7): 1632–1641.
https://doi.org/10.1158/1078-0432.CCR-15-0656
Published: 31 March 2016
View article titled, Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate
Open the PDF for Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate in another window
Includes: Supplementary data
Journal Articles

CCR 20th Anniversary Commentary: Molecular Pathology of ALK-Rearranged Lung Tumors

A. John Iafrate
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (23): 5185–5187.
https://doi.org/10.1158/1078-0432.CCR-14-3130
Published: 30 November 2015
View article titled, <em>CCR</em> 20<sup>th</sup> Anniversary Commentary: Molecular Pathology of <em>ALK</em>-Rearranged Lung Tumors
Open the PDF for <em>CCR</em> 20<sup>th</sup> Anniversary Commentary: Molecular Pathology of <em>ALK</em>-Rearranged Lung Tumors in another window
Journal Articles

Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib

Ryohei Katayama, Luc Friboulet, Sumie Koike, Elizabeth L. Lockerman, Tahsin M. Khan, Justin F. Gainor, A. John Iafrate, Kengo Takeuchi, Makoto Taiji, Yasushi Okuno, Naoya Fujita, Jeffrey A. Engelman, Alice T. Shaw
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (22): 5686–5696.
https://doi.org/10.1158/1078-0432.CCR-14-1511
Published: 13 November 2014
View article titled, Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib
Open the PDF for Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib in another window
Includes: Supplementary data
Journal Articles

Targetable Signaling Pathway Mutations Are Associated with Malignant Phenotype in IDH-Mutant Gliomas

Hiroaki Wakimoto, Shota Tanaka, William T. Curry, Franziska Loebel, Dan Zhao, Kensuke Tateishi, Juxiang Chen, Lindsay K. Klofas, Nina Lelic, James C. Kim, Dora Dias-Santagata, Leif W. Ellisen, Darrell R. Borger, Sarah-Maria Fendt, Matthew G. Vander Heiden, Tracy T. Batchelor, A. John Iafrate, Daniel P. Cahill, Andrew S. Chi
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (11): 2898–2909.
https://doi.org/10.1158/1078-0432.CCR-13-3052
Published: 29 May 2014
View article titled, Targetable Signaling Pathway Mutations Are Associated with Malignant Phenotype in <em>IDH</em>-Mutant Gliomas
Open the PDF for Targetable Signaling Pathway Mutations Are Associated with Malignant Phenotype in <em>IDH</em>-Mutant Gliomas in another window
Includes: Supplementary data
Journal Articles

Circulating Oncometabolite 2-Hydroxyglutarate Is a Potential Surrogate Biomarker in Patients with Isocitrate Dehydrogenase-Mutant Intrahepatic Cholangiocarcinoma

Darrell R. Borger, Lipika Goyal, Thomas Yau, Ronnie T. Poon, Marek Ancukiewicz, Vikram Deshpande, David C. Christiani, Hannah M. Liebman, Hua Yang, Hyeryun Kim, Katharine Yen, Jason E. Faris, A. John Iafrate, Eunice L. Kwak, Jeffrey W. Clark, Jill N. Allen, Lawrence S. Blaszkowsky, Janet E. Murphy, Supriya K. Saha, Theodore S. Hong, Jennifer Y. Wo, Cristina R. Ferrone, Kenneth K. Tanabe, Nabeel Bardeesy, Kimberly S. Straley, Sam Agresta, David P. Schenkein, Leif W. Ellisen, David P. Ryan, Andrew X. Zhu
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (7): 1884–1890.
https://doi.org/10.1158/1078-0432.CCR-13-2649
Published: 31 March 2014
View article titled, Circulating Oncometabolite 2-Hydroxyglutarate Is a Potential Surrogate Biomarker in Patients with Isocitrate Dehydrogenase-Mutant Intrahepatic Cholangiocarcinoma
Open the PDF for Circulating Oncometabolite 2-Hydroxyglutarate Is a Potential Surrogate Biomarker in Patients with Isocitrate Dehydrogenase-Mutant Intrahepatic Cholangiocarcinoma in another window
Includes: Supplementary data
Journal Articles

ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer

Justin F. Gainor, Anna M. Varghese, Sai-Hong Ignatius Ou, Sheheryar Kabraji, Mark M. Awad, Ryohei Katayama, Amanda Pawlak, Mari Mino-Kenudson, Beow Y. Yeap, Gregory J. Riely, A. John Iafrate, Maria E. Arcila, Marc Ladanyi, Jeffrey A. Engelman, Dora Dias-Santagata, Alice T. Shaw
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (15): 4273–4281.
https://doi.org/10.1158/1078-0432.CCR-13-0318
Published: 31 July 2013
View article titled, <em>ALK</em> Rearrangements Are Mutually Exclusive with Mutations in <em>EGFR</em> or <em>KRAS</em>: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer
Open the PDF for <em>ALK</em> Rearrangements Are Mutually Exclusive with Mutations in <em>EGFR</em> or <em>KRAS</em>: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer in another window
Journal Articles

A Novel, Highly Sensitive Antibody Allows for the Routine Detection of ALK-Rearranged Lung Adenocarcinomas by Standard Immunohistochemistry

Mari Mino-Kenudson, Lucian R. Chirieac, Kenny Law, Jason L. Hornick, Neal Lindeman, Eugene J. Mark, David W. Cohen, Bruce E. Johnson, Pasi A. Jänne, A. John Iafrate, Scott J. Rodig
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (5): 1561–1571.
https://doi.org/10.1158/1078-0432.CCR-09-2845
Published: 28 February 2010
View article titled, A Novel, Highly Sensitive Antibody Allows for the Routine Detection of <em>ALK</em>-Rearranged Lung Adenocarcinomas by Standard Immunohistochemistry
Open the PDF for A Novel, Highly Sensitive Antibody Allows for the Routine Detection of <em>ALK</em>-Rearranged Lung Adenocarcinomas by Standard Immunohistochemistry in another window
Includes: Supplementary data
Journal Articles

Polysomy for Chromosomes 1 and 19 Predicts Earlier Recurrence in Anaplastic Oligodendrogliomas with Concurrent 1p/19q Loss

Matija Snuderl, April F. Eichler, Keith L. Ligon, Quynh U. Vu, Michael Silver, Rebecca A. Betensky, Azra H. Ligon, Patrick Y. Wen, David N. Louis, A. John Iafrate
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (20): 6430–6437.
https://doi.org/10.1158/1078-0432.CCR-09-0867
Published: 14 October 2009
View article titled, Polysomy for Chromosomes 1 and 19 Predicts Earlier Recurrence in Anaplastic Oligodendrogliomas with Concurrent 1p/19q Loss
Open the PDF for Polysomy for Chromosomes 1 and 19 Predicts Earlier Recurrence in Anaplastic Oligodendrogliomas with Concurrent 1p/19q Loss in another window
Journal Articles

Integration of Molecular Profiling into the Lung Cancer Clinic

William Pao, Mark G. Kris, A. John Iafrate, Marc Ladanyi, Pasi A. Jänne, Ignacio I. Wistuba, Ryn Miake-Lye, Roy S. Herbst, David P. Carbone, Bruce E. Johnson, Thomas J. Lynch
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (17): 5317–5322.
https://doi.org/10.1158/1078-0432.CCR-09-0913
Published: 31 August 2009
View article titled, Integration of Molecular Profiling into the Lung Cancer Clinic
Open the PDF for Integration of Molecular Profiling into the Lung Cancer Clinic in another window
Journal Articles

Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western Population

Scott J. Rodig, Mari Mino-Kenudson, Sanja Dacic, Beow Y. Yeap, Alice Shaw, Justine A. Barletta, Hannah Stubbs, Kenny Law, Neal Lindeman, Eugene Mark, Pasi A. Janne, Thomas Lynch, Bruce E. Johnson, A. John Iafrate, Lucian R. Chirieac
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (16): 5216–5223.
https://doi.org/10.1158/1078-0432.CCR-09-0802
Published: 12 August 2009
View article titled, Unique Clinicopathologic Features Characterize <em>ALK</em>-Rearranged Lung Adenocarcinoma in the Western Population
Open the PDF for Unique Clinicopathologic Features Characterize <em>ALK</em>-Rearranged Lung Adenocarcinoma in the Western Population in another window
Includes: Supplementary data